Myeloma Minute: Patient Safety Concerns As States Reopen


| EDUCATION | Patient Safety


Patient Safety More Important Than Ever As States Begin to Reopen

The good news is that COVID-19 infections in myeloma patients have been occurring at much lower rates than expected for individuals with compromised immune systems. A major factor keeping them safe has been the protections that all myeloma patients have learned. Dr. Brian G.M. Durie tells how to continue to keep safe as the country begins reopening.


| INSPIRATION | In Memoriam


The IMF Pays Tribute to Our Dear Friend Fred Willard

The entire International Myeloma Foundation team is saddened by the passing of our very dear friend Fred Willard. Through the years, Fred performed at the IMF's Annual Comedy Celebration. We are forever grateful for the countless volunteer performances he gave to his fans at our largest fundraising event of the year. Fred Willard, you will be missed. Rest in peace — from your friends at the International Myeloma Foundation. Watch the video below to remember Fred.


| INSPIRATION | Vacation Getaway



ConversationsPodcastCoverSQ (1).png

And This Too Shall Pass….
Listen to This New Podcast

Once again, the IMF is hosting a raffle for a 10-day stay at the Villa Ono Oasis in historic Kailua-Kona, Hawaii. While many of us have been affected by COVID-19, we hope to remind you that this too shall pass. If you purchase the winning $50 raffle ticket, you could find yourself sipping a tropical beverage next to a private pool, just minutes from the Hawaiian coastline.

Listen now to this new podcast, “Conversations with Dr. Brian G.M. Durie.” In this episode, IMF Chairman of the Board Dr. Durie talks to Sue Dunnett, Senior Lecturer at the University of Edinburgh, about what it means to be resilient.



| ACTION | Research Grants


Calling All Researchers: Submit Your Grant Applications

The Brian D. Novis Research Grants honor the IMF’s founder Brian Novis, who succumbed to multiple myeloma in July of 1992. The grants are awarded to researchers working in the field of multiple myeloma and related disorders, including smoldering multiple myeloma (SMM), monoclonal gammopathy of undetermined significance (MGUS), and immunoglobulin-derived amyloidosis. The 2021 grants will support senior research projects with $80,000 each and junior research projects with $50,000 each. The deadline to receive the applications is Saturday, August 1, 2020.


| EDUCATION | Webinar


Watch a Replay of This Patient & Family Webinar

Watch a replay of this past weekend’s IMF Patient & Family Webinar. This two-hour webinar features a panel discussion about the latest treatments for and management of myeloma led by IMF Chairman Dr. Brian G.M. Durie. Panelists include Dr. Joseph Mikhael of the Translational Genomics Research Institute (TGen), Dr. William Bensinger of the Swedish Medical Center, and Joseph Tariman PhD, RN, from the School of Nursing/College of Science and Health at DePaul University. The IMF is grateful to our sponsors who have who provided virtual resource tables here.


| INNOVATION | Drug News


XPOVIO (Selinexor) Submitted for Supplemental New Drug Application to FDA

On May 20, 2020, Karyopharm Therapeutics “submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for XPOVIO® (Selinexor), its first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, as a new treatment for patients with previously treated multiple myeloma.”


| #ASKDRDURIE | Dr. Durie's Weekly Web Video Series



Search the Myeloma Matrix 2.0

Join the conversation about myeloma on the Smart Patients Message Board

Clinical Trial Fact Sheets

OCEAN Trial (Now Accruing)

IKEMA Trial (Fully Accrued)

IMROZ Trial (Fully Accrued)

BOSTON Trial (Fully Accrued)

Myeloma and Coronavirus
IMF "Living Well with Myeloma"
Webinar Replay

Hawaiian Vacation Raffle
Kailua-Kona, Hawaii

Hatfield Hike
Appalachian Trail

subscribe_button.png     donate_button_bottom.png
We Thank Our Sponsors:
Amgen, Bristol-Myers Squibb, Genentech, GSK, Sanofi-Genzyme, and Takeda Oncology

We also thank individuals like you for your continued support!

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.